<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-127327" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nivolumab</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rendon</surname>
            <given-names>Adriana</given-names>
          </name>
          <aff>Heidelberg University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rayi</surname>
            <given-names>Appaji</given-names>
          </name>
          <aff>Charleston Area Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adriana Rendon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Appaji Rayi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-127327.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Nivolumab is a monoclonal antibody for managing metastatic melanoma and other malignancies. The drug targets the anti-PD1 receptor, an immune checkpoint, thus embodying a potent form of immunotherapy.&#x000a0;This action obstructs the signal that impedes the activation of T-cells against cancerous cells. This&#x000a0;activity&#x000a0;discusses&#x000a0;the drug's indications, mechanism of action, dosing and administration, and adverse event profile, providing essential insights for healthcare professionals involved in treating patients with metastatic melanoma and related conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the appropriate indications for nivolumab therapy in various malignancies based on current clinical guidelines and patient-specific factors.</p></list-item><list-item><p>Screen patients for eligibility and potential contraindications, including autoimmune conditions and concurrent medications that may interact with nivolumab.</p></list-item><list-item><p>Assess and monitor patients for immune-related adverse events using standardized tools and clinical assessments.</p></list-item><list-item><p>Develop collaboration&#x000a0;with oncologists, immunologists, and other specialists to ensure comprehensive and coordinated care for patients receiving nivolumab.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=127327&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=127327">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-127327.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-Approved Indications</bold>
</p>
        <p>Nivolumab is an oncologic drug&#x000a0;in the immune checkpoint inhibitor (ICI) class.&#x000a0;Nivolumab received FDA approval in 2014. Depending on the indication, it can be given as a single agent or in combination with ipilimumab&#x000a0;(anti-CTL4 immune checkpoint inhibitor). Nivolumab is currently FDA-approved for the treatment of:</p>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Melanoma</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Unresectable&#x000a0;or&#x000a0;metastatic melanoma, as a monotherapy or in combination with ipilimumab.</p>
              </list-item>
              <list-item>
                <p>As an adjuvant therapy in lymph node involvement or metastatic disease after complete resection.<xref ref-type="bibr" rid="article-127327.r1">[1]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Non&#x02013;small cell lung&#x000a0;cancer</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Metastatic, with progression during&#x000a0;or after platinum-based chemotherapy (and after progression under targeted therapies for EGFR or&#x000a0;ALK&#x000a0;genomic&#x000a0;tumor&#x000a0;aberrations in case these aberrations are present).<xref ref-type="bibr" rid="article-127327.r2">[2]</xref></p>
              </list-item>
              <list-item>
                <p>As first-line therapy combined with ipilimumab in metastatic or recurrent&#x000a0;non&#x02013;small cell lung cancer&#x000a0;with a PD-L1 expression equal or higher to 1% with no EGFR or ALK genomic tumor aberrations.<xref ref-type="bibr" rid="article-127327.r3">[3]</xref></p>
              </list-item>
              <list-item>
                <p>As first-line therapy in combination with ipilimumab, given with&#x000a0;2 cycles of platinum-doublet chemotherapy.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Renal cell&#x000a0;carcinoma</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>After&#x000a0;prior&#x000a0;anti&#x000ad;angiogenic therapy.</p>
              </list-item>
              <list-item>
                <p>Previously untreated, of intermediate or poor risk, in combination with ipilimumab.<xref ref-type="bibr" rid="article-127327.r4">[4]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Squamous cell&#x000a0;carcinoma of the head and neck</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Recurrent or&#x000a0;metastatic with progressive disease on or following a platinum-based therapy.<xref ref-type="bibr" rid="article-127327.r5">[5]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Pleural Mesothelioma</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>In combination with ipilimumab for unresectable pleural mesothelioma.<xref ref-type="bibr" rid="article-127327.r5">[5]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Small&#x000a0;cell&#x000a0;lung cancer</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Metastatic, with progression after platinum-based chemotherapy and at least&#x000a0;1 additional therapy.<xref ref-type="bibr" rid="article-127327.r6">[6]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Urothelial carcinoma</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Advanced or metastatic, showing disease progression during or after a platinum-based chemotherapy</p>
              </list-item>
              <list-item>
                <p>Progressive disease, within 12 months of neo or adjuvant treatment with platinum-based chemotherapy.<xref ref-type="bibr" rid="article-127327.r7">[7]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Colorectal cancer with microsatellite instability-high&#x000a0;(MSI-H)&#x000a0;or&#x000a0;mismatch&#x000a0;repair&#x000a0;deficient&#x000a0;(dMMR)</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Indicated for patients 12 years and older with metastatic cancer following progression after treatment with fluoropyrimidine, oxaliplatin,&#x000a0;and irinotecan.&#x000a0;Nivolumab can be given as&#x000a0;a&#x000a0;monotherapy&#x000a0;or&#x000a0;in&#x000a0;combination with ipilimumab.</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Hepatocellular carcinoma</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>Following previous&#x000a0;treatment with sorafenib, in combination with ipilimumab</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Classical Hodgkin&#x000a0;lymphoma</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>After relapse or progression following an autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or at least&#x000a0;3 systemic therapies (including autologous HSCT)</p>
              </list-item>
            </list>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>
<bold>Esophageal squamous cell carcinoma</bold>
</p>
          </list-item>
          <list-item>
            <list list-type="bullet">
              <list-item>
                <p>After prior fluoropyrimidine- and platinum-based chemotherapy.<xref ref-type="bibr" rid="article-127327.r8">[8]</xref></p>
              </list-item>
            </list>
          </list-item>
        </list>
      </sec>
      <sec id="article-127327.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Nivolumab is a human monoclonal IgG4 antibody that binds to programmed death-1 (PD-1) receptors with high specificity and affinity. PD-1 is expressed on T-cells and dampens their immune response upon binding ligands PD-L1 and PD-L2 on APCs. This mechanism is pivotal to regulating central and peripheral tolerance.<xref ref-type="bibr" rid="article-127327.r9">[9]</xref></p>
        <p>However, in cancer, aberrant PD-L1 expression by tumor cells or immune cells in the tumor microenvironment deactivates PD-1-expressing tumor-infiltrating lymphocytes, allowing tumor cells to escape immune recognition and elimination.<xref ref-type="bibr" rid="article-127327.r10">[10]</xref><xref ref-type="bibr" rid="article-127327.r11">[11]</xref>&#x000a0;By inhibiting PD-1 function, nivolumab releases immune cells from pathological immune suppression, allowing them to recognize and counter tumor cells.</p>
        <p>
<bold>Pharmacokinetics&#x000a0;</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Pharmacokinetic&#x000a0;research on nivolumab presents linear pharmacokinetics with a dose-proportional increase in peak concentration and area under the curve (AUC). The time to peak plasma concentration ranges between 1&#x000a0;and 4 hours.</p>
        <p><bold>Distribution:</bold>&#x000a0;Nivolumab's mean volume of distribution at steady state is 6.8 L. The drug's coefficient of variation (CV%) is 27.3%.</p>
        <p><bold>Metabolism:&#x000a0;</bold>No&#x000a0;formal studies have examined the specific metabolism of nivolumab. As a human monoclonal antibody, it has been suggested that&#x000a0;the drug&#x000a0;breaks down into small peptides and individual amino acids.</p>
        <p><bold>Elimination:</bold>&#x000a0;No studies regarding nivolumab's specific route of elimination have been conducted. The drug has a half-life of 25 days.</p>
      </sec>
      <sec id="article-127327.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Nivolumab is available as an injectable&#x000a0;solution in a single-dose vial in the following amounts: 40 mg/4 mL (10 mg/mL), 100 mg/10 mL (10 mg/mL), 120 mg/12 mL&#x000a0;(10 mg/mL), and 240 mg/24 mL (10 mg/mL).</p>
        <p>
<bold>Adult Dosing</bold>
</p>
        <p>Nivolumab is administered as an intravenous infusion over 30 minutes. The most common dosing regimens are 240 mg every&#x000a0;2 weeks or 480 mg every&#x000a0;4 weeks. Dosing depends on the indication; practitioners should consult their institutional protocols and package insert&#x000a0;for specific dose regimens. Nivolumab can be diluted in sodium chloride 9 mg/mL (0.9%) solution or in 50 mg/mL (5%) glucose solution for injection. Regardless of the diluent used, immediate use&#x000a0;following solution preparation is advised. Nivolumab may be&#x000a0;given as a combination therapy with ipilimumab for unresectable or metastatic melanoma, advanced renal cell carcinoma, and metastatic&#x000a0;colorectal cancer&#x000a0;(MSI-H or dMMR).</p>
        <p>When given in combination, nivolumab must precede the ipilimumab infusion, and separate infusion bags must be used. In general, nivolumab should not be mixed with or provided on the same intravenous line as another drug. Until it is administered, nivolumab should be stored&#x000a0;refrigerated at 2 &#x000b0;C to 8 &#x000b0;C (36 &#x000b0;F to 46 &#x000b0;F)&#x000a0;and protected from light (in&#x000a0;the original packaging).&#x000a0;The vial should not be frozen or shaken.</p>
        <p>
<bold>Specific Patient Population</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;No adjustment in dosing is necessary for patients with bilirubin values up to 3 times the upper normal limit (UNL) or with AST values &#x0003e; UNL. For patients with bilirubin over 3 times UNL, no data exists.</p>
        <p><bold>Renal impairment:</bold>&#x000a0;No dose adjustment is necessary in patients with a CrCl &#x0003e;15 mL/min. No data exists for patients with a CrCl &#x0003c;15 or on peritoneal or hemodialysis.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Animal studies have&#x000a0;suggested that nivolumab can cause fetal harm when given to pregnant women. The&#x000a0;adverse effects are more prominent in the second and third trimesters. No available human data exists regarding the use of nivolumab in pregnant patients; clinicians should advise pregnant women about potential fetal harm.</p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;No data exists regarding the presence of nivolumab in breast milk. However, due to the potential for severe adverse reactions in breastfeeding children, women are advised not to breastfeed during&#x000a0;nivolumab treatment and for 5 months after the final dose.&#x000a0;</p>
        <p><bold>Pediatric patients: </bold>As with adult dosing,&#x000a0;practitioners should consult their&#x000a0;institutional protocols and package insert&#x000a0;for specific dose regimens.&#x000a0;Research has established the safety and effectiveness of&#x000a0;nivolumab in pediatric patients 12 years and older for the following indications:</p>
        <list list-type="bullet">
          <list-item>
            <p>As a single agent and in conjunction&#x000a0;with ipilimumab&#x000a0;to treat unresectable or metastatic melanoma.</p>
          </list-item>
          <list-item>
            <p>As a&#x000a0;single agent for the adjuvant treatment of melanoma with lymph node involvement or&#x000a0;metastatic disease in pediatric patients who have undergone complete resection.</p>
          </list-item>
          <list-item>
            <p>As a single&#x000a0;agent or in combination therapy with ipilimumab&#x000a0;to treat MSI-H or dMMR mCRC that&#x000a0;has progressed&#x000a0;after treatment with a fluoropyrimidine agent, oxaliplatin, and irinotecan.</p>
          </list-item>
        </list>
        <p><bold>Older patients: </bold>Available&#x000a0;data shows&#x000a0;no overall differences in safety or effectiveness between&#x000a0;older&#x000a0;and younger patients. However, some studies noted an increased incidence of adverse reactions and therapy discontinuation due to adverse reactions in patients&#x000a0;older than age 75.</p>
      </sec>
      <sec id="article-127327.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Severe infusion reactions to nivolumab have been recorded. However, these are uncommon.&#x000a0;In the case of an infusion reaction, therapy must be immediately stopped and symptom-oriented care provided.<xref ref-type="bibr" rid="article-127327.r12">[12]</xref><xref ref-type="bibr" rid="article-127327.r13">[13]</xref>&#x000a0;Due to the drug's T-cell activating mechanism of action, adverse effects&#x000a0;during nivolumab therapy are commonly autoimmune-related. Immune-related adverse events (iRAEs) can affect any given organ system.<xref ref-type="bibr" rid="article-127327.r14">[14]</xref>&#x000a0;</p>
        <p>Some of the adverse effects are transitory and manageable. However, others are life-threatening and require aggressive immunosuppressive therapy and the permanent cessation of the drug.<xref ref-type="bibr" rid="article-127327.r15">[15]</xref>&#x000a0;The most common irAEs involve the gastrointestinal and integumentary systems and usually manifest as a pruritic rash, diarrhea, or colitis. When immune-mediated endocrine inflammation subdues, glandular function may be compromised, thus necessitating permanent hormone substitution. This includes nivolumab-induced hypothyroidism, hypopituitarism, adrenal insufficiency, and diabetes mellitus type 1.<xref ref-type="bibr" rid="article-127327.r16">[16]</xref>&#x000a0;</p>
        <p>Serious adverse reactions include pneumonitis, interstitial lung disease, respiratory failure, pleural effusion, autoimmune neuropathy, and numerous others.&#x000a0;Immune-mediated pneumonitis is a rare adverse effect associated with severe manifestations.<xref ref-type="bibr" rid="article-127327.r17">[17]</xref>&#x000a0;Immune-related myocarditis is a very uncommon adverse event with high lethality.<xref ref-type="bibr" rid="article-127327.r18">[18]</xref>&#x000a0;Less common adverse effects include ocular conditions (eg, uveitis,&#x000a0;conjunctivitis, myositis of periocular muscles), inflammatory hepatitis, endocrinopathies such as hypothyroidism, hypopituitarism, and adrenal insufficiency.<xref ref-type="bibr" rid="article-127327.r19">[19]</xref>&#x000a0;Other rare adverse events include those affecting the neurological system (eg, encephalitis, Guillain-Barr&#x000e9; syndrome).<xref ref-type="bibr" rid="article-127327.r20">[20]</xref><xref ref-type="bibr" rid="article-127327.r21">[21]</xref>&#x000a0;</p>
        <p>There&#x000a0;are reports&#x000a0;that the occurrence of irAEs in patients receiving ICIs correlates with a better outcome.<xref ref-type="bibr" rid="article-127327.r22">[22]</xref>&#x000a0;In particular, low-grade irAEs and those of an endocrine or dermatologic nature were associated with better tumor therapy efficacy.<xref ref-type="bibr" rid="article-127327.r23">[23]</xref><xref ref-type="bibr" rid="article-127327.r24">[24]</xref>&#x000a0;</p>
        <p>The therapy of choice for severe and life-threatening irAEs consists of systemic corticosteroids. Prednisolone is given 1&#x000a0;to 2 mg/kg or intravenously, if necessary, along with prevention for gastric ulcers and osteoporosis.<xref ref-type="bibr" rid="article-127327.r15">[15]</xref>&#x000a0;In steroid-refractory cases, additional immunosuppression with drugs like infliximab, mycophenolate mofetil, or cyclophosphamide.<xref ref-type="bibr" rid="article-127327.r25">[25]</xref>&#x000a0;Intravenous immunoglobulins are also used in grade IV toxicities as an alternative in steroid-refractory cases.<xref ref-type="bibr" rid="article-127327.r26">[26]</xref><xref ref-type="bibr" rid="article-127327.r27">[27]</xref></p>
        <p>Common adverse events include fatigue, musculoskeletal pain, diarrhea, rash, upper respiratory infections, urinary tract infections, and increased ALT or AST. As with more severe reactions, the list is long and generally revolves around the drug's immunosuppressive activity.</p>
        <p><bold>Drug-Drug Interactions</bold>&#x000a0;</p>
        <p>No significant drug-drug interactions&#x000a0;are known for nivolumab. Clinicians should always exercise caution when using multiple drugs.</p>
      </sec>
      <sec id="article-127327.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Boxed Warnings</bold>
</p>
        <p>Nivolumab has no boxed warnings.</p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Contraindications to nivolumab include sensitivity to the drug or its ingredients and multiple myeloma. However, some important settings have not been addressed in clinical studies, such as drug interaction, use in pregnancy, and use during breastfeeding.<xref ref-type="bibr" rid="article-127327.r28">[28]</xref> Some studies on animal models have shown embryofetal toxicity. As human IgG4 is known to cross the placental barrier, there is a potential pathway for transmitting antibodies to a developing fetus.<xref ref-type="bibr" rid="article-127327.r29">[29]</xref> The use of nivolumab during pregnancy should be carefully considered in cases in which the potential benefits outweigh the risks to the patient and fetus.<xref ref-type="bibr" rid="article-127327.r30">[30]</xref> There are literature reports of successful, viable pregnancies in patients who received nivolumab as monotherapy or combined with ipilimumab.<xref ref-type="bibr" rid="article-127327.r31">[31]</xref></p>
        <p>Contraception for at least&#x000a0;5 months after the last dose of nivolumab is strongly advised. Breastfeeding concomitantly to receiving nivolumab therapy is discouraged as antibodies might be passed onto the breast milk. Studies evaluating the fertility of patients receiving nivolumab have not yet been published; it remains unknown whether nivolumab affects either female or male fertility. Patients should be thoroughly informed on this matter, and reproductive counseling should be offered to patients in reproductive age groups. Although preexisting conditions of an autoimmune or inflammatory nature are not a contraindication for nivolumab therapy, it has been reported that such patients have increased rates of immunosuppressive therapy and hospitalization after ICI treatment.<xref ref-type="bibr" rid="article-127327.r32">[32]</xref></p>
      </sec>
      <sec id="article-127327.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Work-up before initiating nivolumab therapy consists of extensive clinical history and physical examination. This includes a thorough baseline clinical assessment of all organ systems. A complete dermatologic assessment, as well as an assessment of gastrointestinal habits and complaints, are essential. Additionally, imaging is necessary to assess potential therapy efficacy. Serologic tests should rule out acute and subclinical infections (<italic toggle="yes">M. tuberculosis</italic>, hepatitis B and C Virus, human-immunodeficiency virus, C<italic toggle="yes">ytomegalovirus</italic>). Laboratory tests required before and during nivolumab therapy include complete blood counts with differential and clinical chemistry, thyroid function tests, liver function tests, and an endocrine panel.<xref ref-type="bibr" rid="article-127327.r14">[14]</xref>&#x000a0;Female patients should have a pregnancy test.</p>
        <p>Monitoring cardiac markers such as troponin I or T is relevant as it can be the only alteration in asymptomatic patients with myocarditis, which carries a high lethality.<xref ref-type="bibr" rid="article-127327.r18">[18]</xref>&#x000a0;Asymptomatic increase of liver transaminases is a common finding and, when pronounced, warrants a work-up to rule out autoimmune-related hepatitis. Periodic follow-up testing includes serum glucose readings and a chest x-ray.</p>
      </sec>
      <sec id="article-127327.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Overdosing&#x000a0;with nivolumab is unlikely and has not been described in the clinical trials. There is no specific treatment for the overdose of nivolumab.&#x000a0;Clinicians and other interprofessional team members must ensure this drug's proper dosage and administration intervals. In case of an overdose, the patient should be placed under strict monitoring, and immediate symptomatic treatment should be provided as soon as signs of adverse reactions occur.<xref ref-type="bibr" rid="article-127327.r33">[33]</xref></p>
      </sec>
      <sec id="article-127327.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The&#x000a0;decision to use nivolumab results from interdisciplinary interaction between clinical oncologists, surgeons, radiologists, radiation oncologists, and&#x000a0;interprofessional tumor boards. Appropriate communication with the patient's family clinician&#x000a0;is warranted, especially if there should be a need to treat mild complications. Proper documentation (ie, medical history, clinical inspection, complimentary test, informed consent) is vital for a reliable interaction between multiple healthcare professionals in the long run. Drug preparation and coordination of transport according to schedule, appropriate labeling, and dosage are essential safety tasks the pharmacy team performs. Nurses&#x000a0;typically administer the intravenous infusion and monitor the patient. They are experts in identifying slight clinical deterioration signs.</p>
        <p>For patients receiving nivolumab or other ICIs, the periodical treatment appointments at the oncologic center become embedded in their life routine. Therefore, an oncologic center delivering nivolumab&#x000a0;should ensure a safe, comfortable, and hygienic environment. The physicians and nurses inform and train the patient to recognize symptoms that could hide developing side effects.&#x000a0;Patients should have an identification card listing the treating clinicians' drug, underlying condition, and contact numbers. A good relationship between the patient and the healthcare team fosters patient compliance. Showing up to appointments according to the treatment schedule ensures safe and effective drug concentrations. Patients undergoing nivolumab treatment may profit from psychological support and nutritional counseling regardless of the tumor entity.</p>
      </sec>
      <sec id="article-127327.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=127327&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=127327">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/127327/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=127327">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-127327.s11">
        <title>References</title>
        <ref id="article-127327.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barrios</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Do</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Postow</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Akaike</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nghiem</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lacouture</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Immune checkpoint inhibitors to treat cutaneous malignancies.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>83</volume>
            <issue>5</issue>
            <fpage>1239</fpage>
            <page-range>1239-1253</page-range>
            <pub-id pub-id-type="pmid">32461079</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pirker</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Immunotherapy combinations in advanced nonsmall cell lung cancer.</article-title>
            <source>Curr Opin Oncol</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>73</fpage>
            <page-range>73-79</page-range>
            <pub-id pub-id-type="pmid">33186185</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ready</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hellmann</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Awad</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Otterson</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Gutierrez</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gainor</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Borghaei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jolivet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Mates</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brahmer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rabinowitz</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Chesney</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Orcutt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Spigel</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Reck</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>O'Byrne</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Paz-Ares</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zerba</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Lestini</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Geese</surname>
                <given-names>WJ</given-names>
              </name>
              <name>
                <surname>Szustakowski</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ramalingam</surname>
                <given-names>SS</given-names>
              </name>
            </person-group>
            <article-title>First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.</article-title>
            <source>J Clin Oncol</source>
            <year>2019</year>
            <month>Apr</month>
            <day>20</day>
            <volume>37</volume>
            <issue>12</issue>
            <fpage>992</fpage>
            <page-range>992-1000</page-range>
            <pub-id pub-id-type="pmid">30785829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albiges</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tannir</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Burotto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McDermott</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Plimack</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Barth&#x000e9;l&#x000e9;my</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Porta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Powles</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Donskov</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kollmannsberger</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Gurney</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Grimm</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Tomita</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Castellano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rini</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Choueiri</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Saggi</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>McHenry</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Motzer</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.</article-title>
            <source>ESMO Open</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>5</volume>
            <issue>6</issue>
            <fpage>e001079</fpage>
            <pub-id pub-id-type="pmid">33246931</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>McCusker</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Mehra</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Emerging immune checkpoint inhibitors for the treatment of head and neck cancers.</article-title>
            <source>Expert Opin Emerg Drugs</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>501</fpage>
            <page-range>501-514</page-range>
            <pub-id pub-id-type="pmid">33196319</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The efficiency and safety of immune checkpoint inhibitors in the treatment of small cell lung cancer: a meta-analysis.</article-title>
            <source>Ann Palliat Med</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>6</issue>
            <fpage>4081</fpage>
            <page-range>4081-4088</page-range>
            <pub-id pub-id-type="pmid">33302668</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tambaro</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Napoli</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Pisano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cecere</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Attademo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rossetti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Feroce</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Setola</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Califano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perdon&#x000e0;</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Izzo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pignata</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>From clinical trials to clinical use of checkpoint inhibitors for patients with metastatic urothelial cancer.</article-title>
            <source>Immunotherapy</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-77</page-range>
            <pub-id pub-id-type="pmid">33045887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kato</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CY</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kadowaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahn</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Hamamoto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Doki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yen</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Kubota</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Hsu</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Holtved</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Xynos</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Kodani</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kitagawa</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial.</article-title>
            <source>Lancet Oncol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>20</volume>
            <issue>11</issue>
            <fpage>1506</fpage>
            <page-range>1506-1517</page-range>
            <pub-id pub-id-type="pmid">31582355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thudium</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>XT</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Feingersh</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kuhne</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Garner</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Leblanc</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bunch</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Blanset</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Selby</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Korman</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates.</article-title>
            <source>Cancer Immunol Res</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>2</volume>
            <issue>9</issue>
            <fpage>846</fpage>
            <page-range>846-56</page-range>
            <pub-id pub-id-type="pmid">24872026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reiss</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Forde</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Brahmer</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy.</article-title>
            <source>Immunotherapy</source>
            <year>2014</year>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>459</fpage>
            <page-range>459-75</page-range>
            <pub-id pub-id-type="pmid">24815784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmadzadeh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Heemskerk</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wunderlich</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Dudley</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Rosenberg</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>Aug</month>
            <day>20</day>
            <volume>114</volume>
            <issue>8</issue>
            <fpage>1537</fpage>
            <page-range>1537-44</page-range>
            <pub-id pub-id-type="pmid">19423728</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kumari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <article-title>Severe infusion reaction due to nivolumab: A case report.</article-title>
            <source>Cancer Rep (Hoboken)</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>e1246</fpage>
            <pub-id pub-id-type="pmid">32671983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>N&#x000fa;&#x000f1;ez Abad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Saval Victoria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Franco La Rosa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Berrocal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Infusion reaction to nivolumab in a metastatic melanoma patient. Safe switch to another anti-programmed death-1: a case report.</article-title>
            <source>Melanoma Res</source>
            <year>2021</year>
            <month>Feb</month>
            <day>01</day>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>88</fpage>
            <page-range>88-91</page-range>
            <pub-id pub-id-type="pmid">33234847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>A Systematic Review and Meta-Analysis of Immune-Related Adverse Events of Anti-PD-1 Drugs in Randomized Controlled Trials.</article-title>
            <source>Technol Cancer Res Treat</source>
            <year>2020</year>
            <season>Jan-Dec</season>
            <volume>19</volume>
            <fpage>1533033820967454</fpage>
            <pub-id pub-id-type="pmid">33084525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgado</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pl&#x000e1;cido</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morgado</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Roque</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Management of the Adverse Effects of Immune Checkpoint Inhibitors.</article-title>
            <source>Vaccines (Basel)</source>
            <year>2020</year>
            <month>Oct</month>
            <day>01</day>
            <volume>8</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">33019641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nada</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bhat</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cousins</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Magnetic resonance imaging criteria of immune checkpoint inhibitor-induced hypophysitis.</article-title>
            <source>Curr Probl Cancer</source>
            <year>2021</year>
            <month>Feb</month>
            <volume>45</volume>
            <issue>1</issue>
            <fpage>100644</fpage>
            <pub-id pub-id-type="pmid">32888700</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bukamur</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Alsharedi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Alkrekshi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shweihat</surname>
                <given-names>YR</given-names>
              </name>
              <name>
                <surname>Munn</surname>
                <given-names>NJ</given-names>
              </name>
            </person-group>
            <article-title>Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab.</article-title>
            <source>South Med J</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>113</volume>
            <issue>11</issue>
            <fpage>600</fpage>
            <page-range>600-605</page-range>
            <pub-id pub-id-type="pmid">33140115</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Palaskas</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lopez-Mattei</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Durand</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Iliescu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Deswal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2020</year>
            <month>Jan</month>
            <day>21</day>
            <volume>9</volume>
            <issue>2</issue>
            <fpage>e013757</fpage>
            <pub-id pub-id-type="pmid">31960755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stuby</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Herren</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Schwegler Naumburger</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Papet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rudiger</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature.</article-title>
            <source>Swiss Med Wkly</source>
            <year>2020</year>
            <month>Nov</month>
            <day>16</day>
            <volume>150</volume>
            <fpage>w20377</fpage>
            <pub-id pub-id-type="pmid">33232507</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haugh</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Probasco</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Neurologic complications of immune checkpoint inhibitors.</article-title>
            <source>Expert Opin Drug Saf</source>
            <year>2020</year>
            <month>Apr</month>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>479</fpage>
            <page-range>479-488</page-range>
            <pub-id pub-id-type="pmid">32126176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Citarella</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Galletti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Russano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gallo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vespasiani-Gentilucci</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Picardi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tonini</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Vincenzi</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Santini</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Steroid-refractory immune related hepatitis may hide viral re-activation.</article-title>
            <source>Future Sci OA</source>
            <year>2020</year>
            <month>Aug</month>
            <day>06</day>
            <volume>6</volume>
            <issue>9</issue>
            <fpage>FSO614</fpage>
            <pub-id pub-id-type="pmid">33235808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdel-Rahman</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Oweira</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Petrausch</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Helbling</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mannhart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mehrabi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sch&#x000f6;b</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Giryes</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.</article-title>
            <source>Expert Rev Anticancer Ther</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>387</fpage>
            <page-range>387-394</page-range>
            <pub-id pub-id-type="pmid">28277102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hussaini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chehade</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boldt</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Raphael</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blanchette</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Maleki Vareki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fernandes</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.</article-title>
            <source>Cancer Treat Rev</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>92</volume>
            <fpage>102134</fpage>
            <pub-id pub-id-type="pmid">33302134</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis.</article-title>
            <source>BMC Med</source>
            <year>2020</year>
            <month>Apr</month>
            <day>20</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <pub-id pub-id-type="pmid">32306958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suresh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Voong</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Shankar</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Forde</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Ettinger</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Marrone</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Hann</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Levy</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Feliciano</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Brahmer</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Feller-Kopman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lerner</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yarmus</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>D'Alessio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hales</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Psoter</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Danoff</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Naidoo</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.</article-title>
            <source>J Thorac Oncol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>12</issue>
            <fpage>1930</fpage>
            <page-range>1930-1939</page-range>
            <pub-id pub-id-type="pmid">30267842</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brahmer</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Lacchetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.</article-title>
            <source>J Oncol Pract</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>247</fpage>
            <page-range>247-249</page-range>
            <pub-id pub-id-type="pmid">29517954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r27">
          <label>27</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Arumugham</surname>
                <given-names>VB</given-names>
              </name>
              <name>
                <surname>Rayi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Intravenous Immunoglobulin (IVIG)</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">32119333</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bucheit</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Hardy</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Szender</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Glitza Oliva</surname>
                <given-names>IC</given-names>
              </name>
            </person-group>
            <article-title>Conception and viable twin pregnancy in a patient with metastatic melanoma while treated with CTLA-4 and PD-1 checkpoint inhibition.</article-title>
            <source>Melanoma Res</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>30</volume>
            <issue>4</issue>
            <fpage>423</fpage>
            <page-range>423-425</page-range>
            <pub-id pub-id-type="pmid">32073510</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Moor</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Walpole</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Atkinson</surname>
                <given-names>VG</given-names>
              </name>
            </person-group>
            <article-title>Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature.</article-title>
            <source>Melanoma Res</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>333</fpage>
            <page-range>333-337</page-range>
            <pub-id pub-id-type="pmid">30730328</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burotto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gormaz</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Samtani</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Valls</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rojas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Porti&#x000f1;o</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de la Jara</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy.</article-title>
            <source>Semin Oncol</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>45</volume>
            <issue>3</issue>
            <fpage>164</fpage>
            <page-range>164-169</page-range>
            <pub-id pub-id-type="pmid">30262400</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Menzer</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Beedgen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rom</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Duffert</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Volckmar</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Sedlaczek</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Richtig</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Enk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>J&#x000e4;ger</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hassel</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy.</article-title>
            <source>Eur J Cancer</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>104</volume>
            <fpage>239</fpage>
            <page-range>239-242</page-range>
            <pub-id pub-id-type="pmid">30454709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bender</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Heilbroner</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>TJC</given-names>
              </name>
              <name>
                <surname>Shu</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Hyde</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Spina</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Increased rates of immunosuppressive treatment and hospitalization after checkpoint inhibitor therapy in cancer patients with autoimmune disease.</article-title>
            <source>J Immunother Cancer</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>8</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">33303578</pub-id>
          </element-citation>
        </ref>
        <ref id="article-127327.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raschi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mazzarella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Antonazzo</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Bendinelli</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Forcesi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tuccori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Moretti</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Poluzzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>De Ponti</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.</article-title>
            <source>Target Oncol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>205</fpage>
            <page-range>205-221</page-range>
            <pub-id pub-id-type="pmid">30927173</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
